Stevanato Group S.p.A. (STVN)

NYSE: STVN · Real-Time Price · USD

16.01

+0.41 (2.63%)

At close: Feb 13, 2026, 4:00 PM EST

16.01

0.00 (0.00%)

After-hours: Feb 13, 2026, 4:10 PM EST

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
EMEA Revenue	692.77M	667.83M	634.05M
EMEA Revenue Growth	3.73%	5.33%	5.73%
APAC Revenue	101.03M	96.24M	102.90M
APAC Revenue Growth	4.98%	-6.48%	2.63%
North America Revenue	321.83M	308.95M	317.54M
North America Revenue Growth	4.17%	-2.71%	26.59%
South America Revenue	29.47M	31.02M	30.87M
South America Revenue Growth	-5.01%	0.49%	-6.08%
Revenue (Other)	-	1,000.00	-
Revenue (Total)	-	1.10B	1.09B
Revenue (Total) Growth	-	1.72%	10.34%

Revenue

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Revenue	976.82M	933.74M	879.29M
Biopharmaceutical and Diagnostic Solutions Revenue Growth	4.61%	6.19%	9.96%
Engineering Revenue	168.28M	170.29M	206.07M
Engineering Revenue Growth	-1.18%	-17.36%	11.97%
Revenue (Total)	-	1.10B	1.09B
Revenue (Total) Growth	-	1.72%	10.34%

Gross Profit

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Gross Profit	298.47M	268.78M	290.23M
Biopharmaceutical and Diagnostic Solutions Gross Profit Growth	11.05%	-7.39%	5.59%
Engineering Gross Profit	47.14M	56.17M	78.26M
Engineering Gross Profit Growth	-16.07%	-28.22%	21.00%
Eliminations from Gross Profit	-24.54M	-22.63M	-28.59M
Gross Profit (Total)	-	302.32M	339.89M
Gross Profit (Total) Growth	-	-11.05%	6.28%

EBIT

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Biopharmaceutical and Diagnostic Solutions Operating Profit	193.51M	165.64M	187.58M
Biopharmaceutical and Diagnostic Solutions Operating Profit Growth	16.83%	-11.70%	2.74%
Engineering Operating Profit	28.95M	33.10M	53.62M
Engineering Operating Profit Growth	-12.53%	-38.27%	29.87%
Eliminations from Operating Profit	-38.58M	-37.59M	-40.47M
Operating Income (Total)	-	161.14M	200.72M
Operating Income (Total) Growth	-	-19.72%	4.31%

Key Performance Indicators

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Backlog	853.00M	944.90M
Backlog Growth	-9.73%	-1.26%

Updated Nov 6, 2025. Data Source: Fiscal.ai.